Study S002277

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes: a Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT04196231
Acronym: BEYOND
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 258
Start: 2019-11-27
Primary completion: 2020-09-30
Lead sponsor: University of Campania Luigi Vanvitelli
Conditions: Type 2 Diabetes
Interventions: DRUG:IDegLira; DRUG:IGlarLixi; DRUG:Insulin/Canaglifozin; DRUG:Insulin/Dapaglifozin; DRUG:Insulin/Empaglifozin; DRUG:Basal Bolus
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Hba1c change [6 months, 9 months, 12 months]
Proportions of patients with significant HbA1c change [Baseline, 3 months, 6 months, 9 months, 12 months, 18 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022468	BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes. Giugliano D, Endocrine	2024	Randomized trial	PMID 37787888 DOI	cites ClinicalTrials.gov:NCT04196231; registry reference DERIVED:37787888
R0011577	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Giugliano D, Diabetes care	2021	Randomized trial	PMID 33883195 DOI	cites ClinicalTrials.gov:NCT04196231; registry reference DERIVED:33883195